MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

MDT

97.17

+1.83%↑

VEEV

296.22

-0.33%↓

A

141.1

+1.69%↑

HQY

89.15

-1.44%↓

PHR.US

23.34

+3.41%↑

Search

Protagonist Therapeutics Inc

Open

SectorGezondheidszorg

64.75 0.34

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

64.46

Max

65.31

Belangrijke statistieken

By Trading Economics

Inkomsten

-23M

-35M

Verkoop

-23M

5.5M

K/W

Sectorgemiddelde

93.057

35.739

Winstmarge

-626.956

Werknemers

130

EBITDA

-23M

-42M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+11.96% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

858M

4.2B

Vorige openingsprijs

64.41

Vorige sluitingsprijs

64.75

Nieuwssentiment

By Acuity

50%

50%

149 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bearish Evidence

Protagonist Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 mrt 2025, 13:59 UTC

Belangrijke Marktbewegers

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Peer Vergelijking

Prijswijziging

Protagonist Therapeutics Inc Prognose

Koersdoel

By TipRanks

11.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 72.75 USD  11.96%

Hoogste 82 USD

Laagste 65 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Protagonist Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

9

Buy

0

Hold

0

Sell

Technische score

By Trading Central

43.62 / 44.27Steun & Weerstand

Korte Termijn

Bearish Evidence

Gemiddeld Termijn

Strong Bullish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

149 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat